Psychotic disorders occurring for the first time in adolescents and young adults pose enormous challenges. Often diagnosis is unclear and potential treatments are not sufficiently evidence-based. Early, appropriate and consistent intervention is necessary in order to optimize outcomes in an early manifestation of a psychotic disorder and we will systematically address a range of issues in this context. Antipsychotic medications are frequently used in these diverse groups. At the same time that their use might be appropriate/efficacious in the short term, there are major unanswered questions regarding their intermediate and long-term use. What are the optimal treatments, dosing and duration of intervention to achieve remission, recovery and to prevent relapse in such individuals? Therapeutic engagement and adherence with treatment are key drivers of outcomes in these populations. As we consider the appropriateness, acceptability and benefit-to-risk ratio of antipsychotic treatments in adolescents and young adults, we also have to consider and address the potential effects of our interventions on global health and, in particular, on those illness and treatment-related factors which contribute so dramatically to increased medical morbidity and mortality in these populations (i.e. weight gain, metabolic syndrome and smoking).The mission of our Center will be to help to establish and support core enabling infrastructure and a series of investigations which can inform critical diagnostic and individual treatment decisions regarding early phase psychotic disorders. We define early phase as being within the first five years following a diagnosis or being in a major high risk category. Under the rubric of high risk and early phase psychotic disorders we include the schizophrenia and bipolar prodrome, schizophreniform disorder, psychosis NOS, substance-induced psychotic disorder, bipolar disorder with psychotic features and schizophrenia or schizoaffective disorder within five years of diagnosis. Ultimately, we hope to improve the outcome (i.e. remission, recovery, functioning, quality of life and global health) of individuals affected by any psychotic illness during a critical stage of development and individuation. Our ability to intervene appropriately, effectively and consistently in this population can have profound long-term public health consequences.
The treatment of adolescents and young adults experiencing the onset of a psychotic illness is fraught with challenges in differential diagnosis and evidence-based treatment decisions, as well as patient engagement, acceptance and adherence. The potential impact of successful early intervention on long term individual and public health outcomes is enormous.
|Nagendra, Arundati; Schooler, Nina R; Kane, John M et al. (2018) Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study. Schizophr Res 193:64-68|
|Karlsgodt, Katherine H; Bato, Angelica A; Ikuta, Toshikazu et al. (2018) Functional Activation During a Cognitive Control Task in Healthy Youth Specific to Externalizing or Internalizing Behaviors. Biol Psychiatry Cogn Neurosci Neuroimaging 3:133-140|
|Browne, Julia; Estroff, Sue E; Ludwig, Kelsey et al. (2018) Character strengths of individuals with first episode psychosis in Individual Resiliency Training. Schizophr Res 195:448-454|
|Robinson, Delbert G; Schooler, Nina R; Correll, Christoph U et al. (2018) Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. Am J Psychiatry 175:169-179|
|Baumel, Amit; Baker, Justin; Birnbaum, Michael L et al. (2018) Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting. Psychiatr Serv 69:590-592|
|John, Majnu; Lencz, Todd; Malhotra, Anil K et al. (2018) A simulations approach for meta-analysis of genetic association studies based on additive genetic model. Meta Gene 16:143-164|
|Kishimoto, Taishiro; Hagi, Katsuhiko; Nitta, Masahiro et al. (2018) Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophr Bull 44:603-619|
|DeRosse, Pamela; Nitzburg, George C; Blair, Melanie et al. (2018) Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults. Schizophr Res 195:385-390|
|Lyall, A E; Pasternak, O; Robinson, D G et al. (2018) Greater extracellular free-water in first-episode psychosis predicts better neurocognitive functioning. Mol Psychiatry 23:701-707|
|Shafritz, Keith M; Ikuta, Toshikazu; Greene, Allison et al. (2018) Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response. Brain Imaging Behav :|
Showing the most recent 10 out of 120 publications